SCHEMBL14129641

SCHEMBL14129641

CC(C)(C)OC(=O)NCCNCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.57
SMN1; SMN2 Q16637 1/20 0.52
PDCD1 Q15116 1/20 0.48
CD274 Q9NZQ7 1/20 0.48
ALOX15 P16050 1/20 0.45
GAA P10253 1/20 0.44
HPGD P15428 1/20 0.44
IDO1 P14902 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
LMNA P02545 2/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
MEN1 O00255 1/20 0.41
ALDH1A1 P00352 1/20 0.41
KMT2A Q03164 1/20 0.41
STK17B O94768 1/20 0.41
STK17A Q9UEE5 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21066511 0.89 PDCD1 (0.46) TSHRSMN1; SMN2PDCD1CD274GAA
SCHEMBL21981673 0.89 CNR2 (0.49) TSHRSMN1; SMN2PDCD1CD274GAA
SCHEMBL1724201 0.85 GAA (0.60) SMN1; SMN2PDCD1CD274GAAIDO1
SCHEMBL25834169 0.85 TSHR (0.54) TSHRSMN1; SMN2GAAHPGDIDO1
SCHEMBL30803476 0.85 CD274 (0.62) SMN1; SMN2PDCD1CD274HPGDIDO1
SCHEMBL22604937 0.84 CD274 (0.53) PDCD1CD274GAAIDO1CA1
SCHEMBL1817391 0.84 TSHR (0.57) TSHRSMN1; SMN2GAAHPGDIDO1
SCHEMBL31500361 0.83 KDM4E (0.54) PDCD1CD274GAAIDO1CYP1A2
SCHEMBL7107994 0.83 KDM4E (0.54) PDCD1CD274GAAIDO1CYP1A2
SCHEMBL14830020 0.83 PYGL (0.53) TSHRSMN1; SMN2CA1CA2STK17B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2008-07-03 US disclosed
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. 2008-07-03 US disclosed
US-7211572-B2 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2007-05-01 US disclosed
US-7211572-B2 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor JAPAN TOBACCO INC. (JP) 2007-05-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161311-A1 Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor DNTT, PNP, NNMT TSHR 4748/4885SMN1; SMN2 2251/4885PDCD1 1963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.